咨询热线:

020-3107 8154

Cisplatin 顺铂; cis-Platinum; CDDP; cis-Diaminodichloroplatinum

Cisplatin是一种无机铂络合物,在肿瘤细胞中能够通过形成DNA加合物抑制 DNA synthesis。Cisplatin 可激活ferroptosis并诱导autophagy。在溶液中不稳定,请现配现用!铂类药物不建议用DMSO溶解,易失活!

  • 货号:
    TK0125
  • 规格:
    10mg
    50mg
    100mg
    500mg
  • 价格:
    0.00

产品参数

CAS No.15663-27-1
生物活性Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.
分子式Cl2H4N2Pt
分子量300.05
储存条件Powder -20℃ 3 years
溶解性数据DMF : 5 mg/mL (16.66 mM; Need ultrasonic; DMSO can inactivate Cisplatin's activity) H2O : 1 mg/mL (3.33 mM; Need ultrasonic; DMSO can inactivate Cisplatin's activity)
体内研究In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight. Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively.
体外研究Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK. Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively.
文献The active components and potential mechanisms of Li-Chong-Xiao-Zhen granules in the treatment of ovarian cancer: An integrated metabolomics, proteomics, network pharmacology and experimental validation
纯度及产品资料98%